A system for auxiliary diagnosis and prognosis assessment of lung cancer based on exosome protein markers
Through an auxiliary lung cancer diagnosis system based on exosomal protein markers, the risk threshold is calculated using the concentration information of specific proteins, and the problem of insufficient early diagnosis sensitivity and specificity of lung cancer in the prior art is solved, and more accurate lung cancer screening and Prognostic evaluation reduces misdiagnosis rates and overdiagnosis.
Patent Information
- Application Number
- CN202411139237.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-20
AI Technical Summary
The sensitivity and specificity of existing early diagnosis biomarkers for lung cancer are low, resulting in poor early diagnosis of lung cancer. Low-dose spiral CT screening has problems with inconsistent definitions of high-risk groups, high false positive rates, overdiagnosis and cost-effectiveness.
Using an auxiliary diagnosis and prognostic evaluation system for lung cancer based on exosomal protein markers, the risk threshold was calculated using the calculation model to obtain the concentration information of seven proteins, including ICAM1, FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2 and TTN. , perform auxiliary diagnosis and prognosis evaluation of lung cancer.
It significantly improves the specificity and sensitivity of lung cancer diagnosis, promotes early diagnosis and screening of lung cancer, and realizes more accurate lung cancer prognosis assessment by detecting signal molecules in small extracellular vesicles, reducing the rate of misdiagnosis and overdiagnosis.
Smart Images

Figure CN118658612B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical diagnosis technology, and in particular to a system for auxiliary diagnosis and prognosis evaluation of lung cancer based on exosome protein markers. Background Art
[0002] Global cancer epidemiological statistics show that in 2020, there will be approximately 2.207 million new cases of lung cancer and approximately 1.796 million new deaths from lung cancer worldwide, accounting for 11.4% and 18.0% of all new cases and deaths from malignant tumors, respectively. According to the latest statistics from the American Cancer Society, it is estimated that there will be approximately 237,000 new cases of lung cancer in the United States in 2022, ranking second among all malignant tumors. Among them, there will be 118,000 and 119,000 cases of lung cancer in men and women, respectively, accounting for 12% and 13% of all new cases of malignant tumors in men and women, respectively. In addition, lung cancer is also the leading cause of death from malignant tumors in the United States. Among deaths from malignant tumors in men and women, approximately 21% are from lung cancer.
[0003] Since lung cancer is highly harmful to human health, promoting and implementing lung cancer screening and early diagnosis and treatment is of great significance for effectively controlling the high mortality rate of lung cancer. Screening and early diagnosis and treatment are the most effective ways to reduce lung cancer deaths and are also the main content of secondary prevention of lung cancer. Low-dose computed tomography (LDCT) is currently the most important means of early screening of lung cancer and has been widely used at home and abroad. However, the application of LDCT has problems such as inconsistent definition standards for high-risk populations, high false positive rates, overdiagnosis and cost-effectiveness. Therefore, finding biomarkers for early diagnosis of lung cancer and optimizing the screening program for patients with early lung cancer are the key to improving the effectiveness of lung cancer screening or preventive treatment.
[0004] In terms of protein tumor marker detection for lung cancer, the commonly used primary lung cancer markers currently recommended by the American Committee on Clinical Biochemistry and the European Tumor Marker Expert Group include carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin fragment 19 (CYFRA21-1), progastrin-releasing peptide (ProGRP), and squamous cell carcinoma antigen (SCC), etc. However, the above protein tumor markers have low sensitivity and specificity in the diagnosis of early lung cancer, resulting in unsatisfactory results in the early diagnosis of lung cancer through protein tumor markers.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a system for auxiliary diagnosis and prognosis evaluation of lung cancer based on exosome protein markers. The system is used for auxiliary diagnosis and / or prognosis evaluation of lung cancer and has high diagnostic sensitivity and specificity.
[0007] The present invention is achieved in that:
[0008] The present invention provides a system for auxiliary diagnosis and / or prognosis evaluation of lung cancer, which comprises: an information acquisition module, and an optional calculation module and / or diagnosis module;
[0009] The information acquisition module is used to execute the step of acquiring the concentration information of the target protein of the subject; the target protein is selected from at least six of the following protein groups: ICAM1, FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2 and TTN;
[0010] The calculation module is used to execute the step of substituting the concentration information into the calculation model to calculate the risk threshold;
[0011] The diagnostic module is used to execute the step of judging the health condition of the subject according to the risk threshold.
[0012] The present invention creatively uses the above target protein as a marker for auxiliary diagnosis or prognosis evaluation of lung cancer, which greatly improves the specificity and sensitivity of lung cancer diagnosis and promotes early diagnosis and screening of lung cancer.
[0013] ICAM1: Intercellular adhesion molecule 1, intercellular adhesion molecule-1;
[0014] FERMT3: Fermitin family homolog 3, Fermitin family homolog 3;
[0015] HSPA5: Endoplasmic reticulum chaperone BiP, endoplasmic reticulum chaperone BiP;
[0016] PRKDC: DNA-dependent protein kinase catalytic subunit, DNA-dependent protein kinase catalytic subunit;
[0017] RELN: Reelin, human reelin;
[0018] TGFBI: Transforming growth factor-beta-induced protein ig-h3, transforming growth factor-beta-induced protein;
[0019] TM9SF1: Transmembrane 9 superfamily member 1, transmembrane protein superfamily 9-1;
[0020] VEGFR2: Vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 2;
[0021] TTN: Titin, human titin.
[0022] It should be noted that the detection method of the above-mentioned target protein can be achieved through chemiluminescence, flow cytometry and other detection platforms currently widely used in medical institutions to measure its concentration information, which is easy to achieve for ordinary technicians in this field.
[0023] Optionally, in some embodiments, the computational model includes a lung cancer auxiliary diagnosis model;
[0024] The lung cancer auxiliary diagnosis model is:
[0025] LCSD = 0.99 × C ICAM1 +1.416×C FERMT3 +1.531×C HSPA5 +0.862×C PRKDC +1.005×C RELN +0.86×C TGFBI +1.234×C TM9SF1 +1.212×C VEGFR2 +0.891×C TTN ;
[0026] Among them, LCSD represents the risk threshold of lung cancer; C ICAM1 , C FERMT3 , C HSPA5 , C PRKDC , C RELN , C TGFBI , C TM9SF1 , C VEGFR2 and C TTN Represent the concentration values of ICAM1, FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2 and TTN, respectively.
[0027] Optionally, in some embodiments, the subject is diagnosed with pulmonary nodules.
[0028] Optionally, in some embodiments, the diagnosis module makes a judgment based on the risk threshold obtained by the lung cancer auxiliary diagnosis model in the following manner:
[0029] If LCSD is less than 360, the subject's pulmonary nodules are judged to be benign; if 360≤LCSD<400, LDCT follow-up or retesting within 1 month is recommended; if LCSD≥400, the subject's pulmonary nodules are judged to be malignant and lung cancer is highly suspected.
[0030] Optionally, in some embodiments, the computational model includes a lung cancer prognosis assessment model;
[0031] The lung cancer prognosis evaluation model is:
[0032] LCS-P=1.340×C ICAM1 +1.916×C FERMT3 +2.072×C HSPA5 +1.361×C RELN +1.671×C TM9SF1 +1.641×C VEGFR2 ;
[0033] Among them, LCS-P represents the risk threshold of lung cancer prognosis; C ICAM1 , C FERMT3 , C HSPA5 , C RELN , C TM9SF1 and C VEGFR2 Represent the concentration values of ICAM1, FERMT3, HSPA5, RELN, TM9SF1 and VEGFR2, respectively.
[0034] It should be noted that the fixed coefficients (such as 0.99, 1.34, 1.916, etc.) in the calculation formula of the above model can fluctuate within a certain range, such as ±3%. Therefore, in other embodiments, as long as the calculation model is within this range, it belongs to the protection scope of the present invention.
[0035] Optionally, in some embodiments, the unit of concentration value is IU / mL (protein concentration in sEV per mL of plasma).
[0036] Optionally, in some embodiments, the subject is a patient who has undergone lung cancer treatment.
[0037] Optionally, in some embodiments, the diagnostic module makes a judgment based on the risk threshold obtained by the lung cancer prognosis assessment model in the following manner:
[0038] If LCS-P≤240, it is judged as a low score, indicating that the subject has extremely low micro-residual lung cancer cells and a good prognosis; if LCS-P>320, it is judged as a high score, indicating that the subject has micro-residual lung cancer cells and a short-term recurrence risk, and requires continuous clinical treatment intervention; if 240<LCS-P≤320, it is recommended to retest within 1 month.
[0039] Alternatively, in some embodiments, the target protein is from small extracellular vesicles in the subject's plasma.
[0040] Small extracellular vesicles (sEV, small Extracellular Vesicle, also called exosomes) are secreted by cells, with a diameter of 40-150nm, and can circulate in body fluids such as blood and urine. This type of vesicle carries signal molecules derived from mother cells. The vesicles secreted by tumor cells can transport important signal molecules in the microenvironment where the tumor occurs, promoting the progression and metastasis of the tumor. Therefore, detecting signal molecules derived from small extracellular vesicles for early screening, diagnosis and prognosis monitoring of tumors is the focus of current scientific research and industrial transformation. The present invention creatively identified the above 9 protein markers from small extracellular vesicles for auxiliary diagnosis or prognosis evaluation of lung cancer, which greatly improved the specificity and sensitivity of lung cancer diagnosis using protein markers.
[0041] It should be noted that the methods for extracting, separating and enriching plasma small extracellular vesicles used in the present invention can be carried out using conventional techniques and kits in the art, which are easily implemented by those skilled in the art.
[0042] Optionally, in some embodiments, the system further comprises a result display module, and the result display module is used to display the diagnosis result obtained by the diagnosis module.
[0043] Optionally, in some embodiments, the result display module displays the diagnosis result by screen display, voice broadcast or printing. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0045] Figure 1The data of 9 plasma sEV-derived protein targets detected by chemiluminescence in 50 patients with T1 lung adenocarcinoma and 30 age-matched healthy controls. ICAM1 was highly expressed in healthy controls, and the other 8 protein targets were highly expressed in patients with early lung adenocarcinoma. **** represents p value<0.0001.
[0046] Figure 2 The results of Pearson correlation analysis of mass spectrometry data of 80 plasma sEVs by PRM method (after normalization) and ECL method (after normalization). The correlation R value of ICAM1 target in the two groups of data is 0.69, the correlation R value of RELN target in the two groups of data is 0.86, and the correlation R value of TM9SF1 target in the two groups of data is 0.74.
[0047] Figure 3 The data of transmembrane protein targets TGFBI, TM9SF1 and VEGFR2 in plasma sEV of esophageal cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer patients and healthy control group were detected by ECL method. The expression levels of membrane protein targets TGFBI and VEGFR2 in four digestive tract tumor samples were not different from those in the healthy group, and were only highly expressed in plasma sEV of lung cancer patients. TM9SF1 was highly enriched in all tumor samples except the healthy control group, and was a sEV target protein common to multiple cancer types.
[0048] Figure 4 The ROC curve was generated for the LCSD values of 141 samples, and its AUC was 0.980, which means that the sensitivity of this model for auxiliary diagnosis of benign and malignant pulmonary nodules was 94.10% and the specificity was 100%.
[0049] Figure 5 The ROC curve was generated for the LCSD values of 30 samples of non-solid nodules, and its AUC was 0.985, which means that the sensitivity of this model for auxiliary diagnosis of benign and malignant non-solid pulmonary nodules was 95.30% and the specificity was 100%.
[0050] Figure 6 The prognostic survival curves of 128 patients with non-small cell lung cancer whose postoperative pathology was IIA to IIIA were drawn using a prognostic evaluation model. The subjects in the high-score LCS-P group had micro-residual lung cancer cells and a short-term recurrence risk, requiring continuous clinical treatment intervention, with an average survival of less than 1 year (about 9.7 months). The subjects in the low-score LCS-P group had extremely low micro-residual lung cancer cells, with an average survival of more than 2 years (about 24.7 months). DETAILED DESCRIPTION
[0051] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0052] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0053] Example 1
[0054] Discovery of protein markers.
[0055] 1. Obtain 50 samples of lung cancer tissues and corresponding adjacent tissues that were pathologically diagnosed as T1 after surgery, separate tissue-derived sEVs, extract sEV total protein, and perform enzymatic hydrolysis to quantify the final peptide of each sample to 0.2 μg / μL (total amount not less than 10 μg);
[0056] 2. Load the samples onto the machine and test them through the Orbitrap LC-MS (Liquid Chromatography Mass Spectrometry) platform, and use Thermo Scientific Proteome Discoverer software to obtain quantitative information of 100 sEV protein samples;
[0057] 3. Using the R language package DEqMS, we analyzed the differentially expressed proteins in sEVs from 50 tumor tissues and 50 para-cancerous tissues, and obtained 350 proteins highly expressed in sEVs from tumor tissues and 161 proteins highly expressed in sEVs from para-cancerous tissues;
[0058] 4. The 511 protein expression data of 100 samples were randomly divided into a training set of 70 and a validation set of 30 according to the screening criteria that the training set includes at least 10 adjacent cancer control groups and the validation set includes at least 10 adjacent cancer control groups. The random grouping was performed for 50 rounds, and the random forest machine learning model was used to screen lung cancer-specific proteins in each round to obtain 50 groups of lung cancer tissue sEV-specific protein expression profiles;
[0059] 5. The protein expression profiles of the above 50 rounds were intersected to obtain 26 protein combinations, including 22 proteins highly expressed by sEV in tumor tissues and 4 proteins highly expressed by sEV in adjacent tissues;
[0060] 6. Use the PRM (Parallel Reaction Monitoring) detection platform to conduct a new round of testing on the 26 protein combinations in the plasma sEV proteins of lung cancer, esophageal cancer, gastric cancer, liver cancer, colorectal cancer and healthy volunteers whose age matches that of tumor patients, and obtain 26 protein expression profiles of 120 plasma sEVs. According to the screening criteria that the training set includes at least 10 lung cancer plasma sEV data and the validation set includes at least 10 healthy plasma sEVs, the 120 samples were randomly divided into a training set of 80 and a validation set of 40. The random grouping was performed for 60 rounds, and the random forest machine learning model was used in each round to screen the lung cancer plasma sEV-specific proteins, and 60 groups of lung cancer plasma sEV-specific protein expression profiles were obtained;
[0061] 7. The protein expression profiles of the above 60 rounds were intersected, and finally 9 protein combinations were obtained, including 8 proteins FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2 and TTN that were highly expressed in lung cancer plasma sEV, and 1 protein ICAM1 that was lowly expressed in lung cancer plasma sEV.
[0062] Example 2
[0063] The detection of 9 protein targets derived from plasma sEVs showed statistical differences, which has clinical value in the diagnosis of lung cancer.
[0064] The sEV protein samples (50 cases of T1 NSCLC (Non-Small Cell Lung Cancer) group and 30 cases of healthy group) using PRM targeted protein spectrum were detected by chemiluminescence instrument to obtain the 9 protein target values of random forest machine learning model. The results are shown in Figure 1 .
[0065] The plasma sEV-derived ICAM1 in the NSCLC group was 25.67±12.52 IU / mL, while that in the healthy control group was 97.28±23.60 IU / mL.
[0066] FERMT3 in the NSCLC group was 70.33±43.30 IU / mL, and that in the healthy control group was 14.04±7.37 IU / mL.
[0067] HSPA5 in the NSCLC group was 255.35±152.34 IU / mL, and in the healthy control group was 5.68±1.29 IU / mL.
[0068] PRKDC in the NSCLC group was 32.53±7.56 IU / mL, and in the healthy control group it was 23.82±4.19 IU / mL.
[0069] RELN in the NSCLC group was 108.03±57.66 IU / mL, and that in the healthy control group was 33.83±9.39 IU / mL.
[0070] TGFBI in the NSCLC group was 650.07±318.42 IU / mL, and that in the healthy control group was 275.82±97.22 IU / mL.
[0071] TM9SF1 in the NSCLC group was 72.53±49.46 IU / mL, and in the healthy control group it was 18.03±12.28 IU / mL.
[0072] VEGFR2 in the NSCLC group was 177.70±104.43 IU / mL, and in the healthy control group was 37.45±20.36 IU / mL.
[0073] TTN was 114.32±61.02 IU / mL in the NSCLC group and 59.29±29.71 IU / mL in the healthy control group (****p<0.0001).
[0074] Among them, ICAM1 was highly expressed in the healthy group, and the other eight protein targets were all highly expressed in the NSCLC group, and there were very significant statistical differences between the two groups, which preliminarily showed the effective diagnostic value of these nine protein targets for lung cancer.
[0075] Example 3
[0076] The data of protein targets in PRM targeted proteomics are highly correlated with the data of protein targets detected by chemiluminescence instrument.
[0077] The data (after normalization) from the PRM detection of plasma sEVs from 50 NSCLC patients and 30 healthy controls were used as the Y-axis, and the data (after normalization) from the chemiluminescence (ECL) detection of these 80 plasma sEV samples were used as the X-axis. The Pearson correlation coefficient of the two groups of normalized data was calculated to analyze the data correlation of the same sample obtained by the two detection methodologies. Among them, the correlation R value of the ICAM1 target in the two groups of data was 0.69, the correlation R value of the RELN target in the two groups of data was 0.86, and the correlation R value of the TM9SF1 target in the two groups of data was 0.74. It can be analyzed that both the targeted mass spectrometry PRM method and the clinical conventional chemiluminescence method can effectively detect lung cancer-specific targets, and the data correlation between different methodologies is high. The results are shown in Figure 2 .
[0078] Example 4
[0079] Membrane protein targets are highly specific to lung cancer.
[0080] sEVs secreted by tumor cells have biological specificity of the source cells, especially the membrane proteins of tissue-specific origin contained on the sEV membrane. Among the 9 protein targets with diagnostic value for lung cancer in the present invention, 3 are transmembrane proteins belonging to sEVs, namely TGFBI, TM9SF1 and VEGFR2. The 30 healthy groups, 10 esophageal cancer, 10 gastric cancer, 10 hepatocellular carcinoma and 10 colorectal cancer samples in the plasma test set were tested by chemiluminescence to obtain data.
[0081] Statistical confirmation showed that the expression levels of membrane protein targets TGFBI and VEGFR2 in the four gastrointestinal tumor samples were no different from those in the healthy group.
[0082] The average values of TGFBI in samples of each group were: 275.82 IU / mL (Health), 298.00 IU / mL (EC), 291.69 IU / mL (GC), 285.58 IU / mL (HCC), 260.76 IU / mL (ColC);
[0083] The average values of VEGFR2 in samples from each group were: 37.45 IU / mL (Health), 33.89 IU / mL (EC), 41.30 IU / mL (GC), 34.29 IU / mL (HCC), and 29.68 IU / mL (ColC).
[0084] EC: Esophageal Cancer; GC: Gastric Cancer; HCC: Hepato-Cellular Cancer; ColC: Colorectal Cancer.
[0085] Combined with the data results in Example 2, it can be determined that these two sEV transmembrane protein targets are highly enriched only in the lung cancer group, and are specific sEV target proteins derived from lung cancer. In addition, the average values of TM9SF1 in samples from each group are: 18.03IU / mL (Health), 116.30IU / mL (EC), 116.56IU / mL (GC), 147.42IU / mL (HCC), 126.65U / mL (ColC), so TM9SF1 is highly enriched in all tumor samples except the healthy group, and is a sEV target protein common to multiple cancers (see Figure 3 ).
[0086] Example 5
[0087] Chemiluminescence scoring model for malignant pulmonary nodules and its clinical diagnostic efficacy.
[0088] The lung cancer diagnosis model containing 9 proteins finally obtained through random forest machine learning is:
[0089] LCSD=0.990×ICAM1(IU / mL)+1.416×FERMT3(IU / mL)+1.531×HSPA5(IU / mL)+0.862×PRKDC(IU / mL)+1.005×RELN(IU / mL)+0.860×TGFBI(IU / mL)+1.234×TM9SF1(IU / mL)+1.212×VEGFR2(IU / mL)+0.891×TTN(IU / mL). If LCSD<360, the pulmonary nodule model was evaluated as benign; if 360≤LCSD<400, the LCSD model was retested within 1 month after LDCT follow-up; if LCSD≥400, the pulmonary nodule model was evaluated as malignant, and lung cancer was highly suspected.
[0090] A total of 200 subjects with lung nodules within 5-10 mm screened by LDCT were enrolled. The LCSD model was used to identify malignant lung nodules in these 200 subjects. The clinical pathological diagnosis results after 12 months of follow-up were compared with the model results to evaluate the sensitivity and specificity of the auxiliary diagnosis model for distinguishing benign and malignant small lung nodules (see Table 1 below). Excluding 55 cases lost to follow-up and 4 cases without clear pathological diagnosis conclusions, the LCSD values of 141 samples were used to generate the ROC curve ( Figure 4 ), with AUC = 0.980, indicating that the sensitivity of this model for auxiliary diagnosis of benign and malignant pulmonary nodules is 94.10% and the specificity is 100%. The ROC curve was generated using only the LCSD values of the 30 samples with non-solid nodules shown on LDCT ( Figure 5 ), with an AUC of 0.985, indicating that the sensitivity of this model for auxiliary diagnosis of benign and malignant non-solid pulmonary nodules is 95.30% and the specificity is 100%.
[0091] Table 1
[0092] Pulmonary nodules (5-10 mm on low-dose CT) LCSD diagnosis results Pathological diagnosis results of 12-month follow-up 111 cases of solid 109 benign cases; 2 malignant cases 110 cases were benign; 1 case had no pathological diagnosis Partial solid 21 cases 14 cases were benign; 7 cases were malignant 14 cases were benign; 6 cases were lung adenocarcinoma; 1 case had no pathological diagnosis 13 cases of non-substantial 1 benign case; 12 malignant cases 1 case of benign disease; 9 cases of lung adenocarcinoma; 2 cases without pathological diagnosis
[0093] Example 6
[0094] Flow cytometry-based scoring model for lung cancer prognosis monitoring and its clinical diagnostic efficacy.
[0095] The lung cancer prognosis evaluation model containing 6 proteins finally obtained by random forest machine learning is: LCS-P=1.340×ICAM1(IU / mL)+1.916×FERMT3(IU / mL)+2.072×HSPA5(IU / mL)+1.361×RELN(IU / mL)+ 1.671×TM9SF1(IU / mL)+1.641×VEGFR2(IU / mL). Among them, LCS-P≤240 is a low score, and LCS-P>320 is a high score. When the test value of the subject is 240<LCS-P≤320, it is recommended to retest within 1 month.
[0096] A total of 128 patients with non-small cell lung cancer whose postoperative pathology was IIA to IIIA were enrolled. The prognostic evaluation model was used to evaluate the prognosis of the subjects, and the subjects were followed up until tumor recurrence or death. Tumor recurrence or death due to tumor was recorded as 1, and the corresponding time was recorded. No tumor recurrence was recorded as 0, and the corresponding time was recorded.
[0097] The patients were grouped into high LCS-P (High LCS-P) and low LCS-P (Low LCS-P) scores, and whether tumor recurrence or death due to tumor occurred in the same prognostic time interval was recorded to generate a table (see Table 2 below).
[0098] The table is used to draw the prognosis survival curve of the subjects (see Figure 6 ). The statistical results confirm that the subjects in the high-score LCS-P group have micro-residues of lung cancer cells and the risk of short-term recurrence, and need continuous clinical treatment intervention, otherwise the subjects have a poor prognosis, with an average survival period of less than 1 year (about 9.7 months). The subjects in the low-score LCS-P group have very low micro-residues of lung cancer cells, a good prognosis, and an average survival period of more than 2 years (about 24.7 months) (see Figure 6 ).according to Figure 6 From Table 2 , it can be shown that the positive predictive value of a subject passing LCS-P within 12 months after surgery is 74.55%, and the negative predictive value is 85.71%.
[0099] Table 2
[0100] Month High LCS-P Low LCS-P 3.2 1 0 3.4 1 0 3.8 1 0 3.8 1 0 3.9 1 0 3.9 1 0 4 1 0 4 0 0 4.3 1 - 4.3 1 4.4 1 0 4.4 1 0 4.7 1 4.7 1 4.9 0 0 5 0 5.3 0 1 5.5 1 0 5.5 1 0 5.7 1 0 6 0 0 6.2 1 0 6.3 0 0 6.9 0 1 6.9 1 0 7 0 7.1 1 7.2 1 0 7.4 1 7.7 1 0 7.8 1 0 8 1 1 8.1 1 0 8.7 0 0 8.8 1 0 8.9 1 0 9.7 1 0 9.9 1 0 10.2 0 1 11.3 1 1 11.9 0 0 12 1 0 12.1 0 0 12.5 1 12.8 1 13 1 13.6 0 13.7 1 1 14.2 1 14.9 0 0 15.1 0 15.8 0 16.6 1 1 16.9 0 17.3 1 0 17.9 1 18 1 1 18 0 18.2 0 18.8 0 19 0 0 19.1 0 1 19.7 1 1 19.9 1 0 20.3 0 0 20.7 0 21 0 21.4 1 0 22 0 22.5 22.7 0 0 23 0 1 23.3 0 23.5 0 24.3 0 24.7 1 25 0 25.5 0 25.7 26.1 26.4 0 27.7 28.5 0 28.8
[0101] In the table: Month is the recorded time from the beginning of surgery to the occurrence of recurrence or death. The subjects are divided into two groups, High and Low, according to the LCS-P value. Then, if 1 appears in the High group at 3.2 months, it means that a subject has died, and if 0 appears in the Low group, it means that at 3.2 months, the subject is still in the survival stage. For example, at the 6th month, if both the High and Low groups are 0, it means that during this statistical period, there is 1 subject in each group who is in the survival stage. A blank space means that there is no subject in this group during this time period.
[0102] Example 7
[0103] This example provides a method for detecting nine lung cancer-specific proteins in plasma sEV using a chemiluminescence platform, comprising the following steps:
[0104] 1. Purify plasma sEVs and extract sEV-derived total protein;
[0105] 1.1. Centrifuge 3 mL of whole blood separated from the anticoagulation blood collection tube at 2000 × g for 10 minutes at room temperature and draw 1 mL of upper plasma;
[0106] 1.2. Turn on the automatic sEV separator ExoStation (brand: Shengran Technology, model: G1000). After the instrument self-check is completed, click the plasma - sample volume 1mL - high-purity sEV component buttons on the screen in sequence;
[0107] 1.3. Add 1 mL of plasma to the sEV purification reagent 500 UltraColumn (brand: Shengran Technology) pre-placed in the ExoStation, close the operation window and click the start button on the screen interface. After hearing the prompt tone indicating that the purification is complete, open the operation window and take out the EP tube that has completed sEV separation;
[0108] 1.4. Add 0.5 mL of RIPA lysis and extraction buffer (ThermoFisher, Cat. No. 89900) to the EP tube and incubate at room temperature for 5 minutes to complete the extraction of total protein from sEVs.
[0109] 2. Prepare magnetic beads coated with antibodies corresponding to 9 proteins;
[0110] 2.1. Wash the magnetic beads and dilute the washed magnetic beads (brand: ThermoFisher, catalog number: 21353) to 0.2 mg / mL;
[0111] 2.2. Dilute the primary antibodies corresponding to the 9 proteins to 1:100 (Brand Abcam, anti-ICAM1 Catalog No.: ab222736; Brand ThermoFisher, anti-FERMT3 Catalog No.: PA5-30847; Brand Abcam, anti-HSPA5 Catalog No.: ab290692; Brand ThermoFisher, anti-RELN Catalog No.: PA5-78413; Brand Abcam, anti-TGFBI Catalog No.: ab170874; Brand ThermoFisher, anti-PRKDC Catalog No.: MA5-32192; anti-TM9SF1 Catalog No.: PA5-84406; Brand Abcam, anti-VEGFR2 Catalog No.: ab115805; Brand ThermoFisher, anti-TTN Catalog No.: PA5-68473), and incubate the diluted primary antibodies with the washed magnetic beads at 37°C for 1 hour to complete the coating;
[0112] 2.3. Add BSA to the coated antibody magnetic bead mixture for blocking, react at 37°C for 1 hour, wash off the excess BSA, and finally place the blocked antibody magnetic bead solution at 4°C until use.
[0113] 3. Prepare ALP-labeled primary antibody;
[0114] According to the instructions of the ALP coupling kit - Lightning-Link® (brand: Abcam, catalog number: ab102850), the 9 primary antibodies in step 2 were labeled with ALP and set aside.
[0115] 4. Incubate the magnetic beads, plasma sEV protein and ALP labeled primary antibody;
[0116] 4.1. Prepare 9 EP tubes, add 50 μL of plasma sEV protein extract, 50 μL of each primary antibody magnetic bead mixture and 5 μL of each ALP labeled primary antibody respectively and incubate at 37°C for 10 minutes;
[0117] 4.2. Wash and remove excess ALP labeled primary antibody and plasma sEV protein, leaving only the double sandwich magnetic beads plasma sEV protein and ALP after incubation
[0118] The complex was washed twice and then prepared for the luminescence reaction.
[0119] 5. Chemiluminescence reaction and numerical reading;
[0120] 5.1. Add the ALP reaction substrate AMPPD (MedChemExpress, Catalog No.: 122341-56-4) to the complex and react at room temperature for 1 minute in the dark;
[0121] 5.2. The solution after the reaction was placed in a fully automatic chemiluminescence immunoassay analyzer (brand: Cosmay, model: Venus100) for numerical reading.
[0122] In summary, the embodiment of the present invention identified a group of 9 protein target combinations specific to non-small cell lung cancer through a large number of clinical samples. Some or all of the specific protein targets in this group can be used for the early benign and malignant evaluation of small lung nodules, and can also be used for the prognosis evaluation of patients with lung cancer after surgery in the middle and late stages. The value of this group of specific protein targets in the clinical diagnosis and treatment of lung cancer has been verified and tested through a large number of clinical samples. In addition, the above-mentioned protein targets identified by protein spectrum can be routinely detected through a variety of commonly used clinical testing technology platforms such as chemiluminescence, flow cytometry and targeted protein spectrum PRM, which is convenient for clinical application and promotion.
[0123] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A system for auxiliary diagnosis and / or prognosis assessment of lung cancer based on exosome protein markers, It is characterized in that It includes: an information acquisition module, and an optional calculation module and / or diagnosis module; The information acquisition module is used to execute the step of acquiring the concentration information of the target protein of the subject; the target protein is selected from at least six of the following protein groups: ICAM1, FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2 and TTN; The calculation module is used to execute the step of substituting the concentration information into the calculation model to calculate the risk threshold; The diagnostic module is used to perform the step of determining the health condition of the subject according to the risk threshold; The computational model includes a lung cancer auxiliary diagnosis model and / or a lung cancer prognosis assessment model; The lung cancer auxiliary diagnosis model is: LCSD=0.990×C ICAM1 +1.416×C FERMT3 +1.531×C HSPA5 +0.862×C PRKDC +1.005×C RELN +0.860×C TGFBI +1.234×C TM9SF1 +1.212×C VEGFR2 +0.891×C TTN ; Among them, LCSD represents the risk threshold of lung cancer; C ICAM1 , C FERMT3 , C HSPA5 , C PRKDC , C RELN , C TGFBI , C TM9SF1 , C VEGFR2 and C TTN represent the concentration values of ICAM1, FERMT3, HSPA5, PRKDC, RELN, TGFBI, TM9SF1, VEGFR2, and TTN, respectively; The lung cancer prognosis evaluation model is: LCS-P=1.340×C ICAM1 +1.916×C FERMT3 +2.072×C HSPA5 +1.361×C RELN +1.671×C TM9SF1 +1.641×C VEGFR2 ; Among them, LCS-P represents the risk threshold of lung cancer prognosis; C ICAM1 , C FERMT3 , C HSPA5 , C RELN , C TM9SF1 and C VEGFR2 Represent the concentration values of ICAM1, FERMT3, HSPA5, RELN, TM9SF1 and VEGFR2, respectively.
2. The system according to claim 1, It is characterized in that When the subject is diagnosed with having small lung nodules, the diagnosis module makes a judgment based on the risk threshold obtained by the lung cancer auxiliary diagnosis model in the following manner: If LCSD is less than 360, the subject's pulmonary nodules are judged to be benign; if 360≤LCSD<400, LDCT follow-up or retesting within 1 month is recommended; if LCSD≥400, the subject's pulmonary nodules are judged to be malignant and lung cancer is highly suspected.
3. The system according to claim 1, It is characterized in that When the subject is a patient who has undergone lung cancer treatment; The diagnosis module makes a judgment based on the risk threshold obtained by the lung cancer prognosis assessment model in the following manner: If LCS-P≤240, it is judged as a low score, indicating that the subject has extremely low micro-residual lung cancer cells and a good prognosis; if LCS-P>320, it is judged as a high score, indicating that the subject has micro-residual lung cancer cells and a short-term recurrence risk, and requires continuous clinical treatment intervention; if 240<LCS-P≤320, it is recommended to retest within 1 month.
4. The system according to any one of claims 1 to 3, It is characterized in that The target protein is derived from small extracellular vesicles in the subject's plasma.
5. The system according to any one of claims 1 to 3, It is characterized in that The system further comprises a result display module, and the result display module is used to display the diagnosis result obtained by the diagnosis module.
6. The system according to claim 5, It is characterized in that The result display module displays the diagnosis result by screen display, voice broadcast or printing.
